全文获取类型
收费全文 | 1910篇 |
免费 | 181篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 96篇 |
妇产科学 | 34篇 |
基础医学 | 241篇 |
口腔科学 | 25篇 |
临床医学 | 168篇 |
内科学 | 501篇 |
皮肤病学 | 56篇 |
神经病学 | 120篇 |
特种医学 | 97篇 |
外科学 | 242篇 |
综合类 | 106篇 |
预防医学 | 128篇 |
眼科学 | 10篇 |
药学 | 141篇 |
中国医学 | 3篇 |
肿瘤学 | 126篇 |
出版年
2021年 | 21篇 |
2020年 | 17篇 |
2019年 | 23篇 |
2018年 | 35篇 |
2017年 | 20篇 |
2016年 | 23篇 |
2015年 | 36篇 |
2014年 | 49篇 |
2013年 | 58篇 |
2012年 | 86篇 |
2011年 | 87篇 |
2010年 | 77篇 |
2009年 | 80篇 |
2008年 | 102篇 |
2007年 | 90篇 |
2006年 | 59篇 |
2005年 | 62篇 |
2004年 | 58篇 |
2003年 | 67篇 |
2002年 | 56篇 |
2001年 | 51篇 |
2000年 | 53篇 |
1999年 | 61篇 |
1998年 | 55篇 |
1997年 | 32篇 |
1996年 | 40篇 |
1995年 | 29篇 |
1994年 | 37篇 |
1993年 | 23篇 |
1992年 | 41篇 |
1991年 | 40篇 |
1990年 | 37篇 |
1989年 | 33篇 |
1988年 | 25篇 |
1987年 | 30篇 |
1986年 | 37篇 |
1985年 | 32篇 |
1984年 | 23篇 |
1983年 | 33篇 |
1982年 | 22篇 |
1981年 | 18篇 |
1980年 | 22篇 |
1979年 | 25篇 |
1978年 | 16篇 |
1977年 | 13篇 |
1976年 | 19篇 |
1975年 | 14篇 |
1974年 | 13篇 |
1973年 | 17篇 |
1970年 | 15篇 |
排序方式: 共有2098条查询结果,搜索用时 0 毫秒
41.
42.
Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? 总被引:1,自引:0,他引:1
Richardson K Baillie A Reid S Morley K Teesson M Sannibale C Weltman M Haber P 《Addiction (Abingdon, England)》2008,103(6):953-959
AIM: To explore the effect of acamprosate and naltrexone on craving and alcohol consumption in the treatment of alcohol dependence. DESIGN: A randomized, double-blind, single-dummy, placebo-controlled trial. SETTING: Three treatment centres in Sydney, Australia. PARTICIPANTS: A total of 169 alcohol-dependent subjects were given naltrexone (50 mg/day), acamprosate (1998 mg/day) or placebo for 12 weeks, in conjunction with manualized medication compliance therapy. INTERVENTION: During the course of the trial, participants kept a daily diary which included the number of standard drinks they consumed and their peak craving for alcohol that day rated on a 0-10 scale. MEASUREMENTS: Subjective ratings of daily craving and daily drinking for the first 6 weeks of treatment. FINDINGS: Mixed/hierarchical linear models were employed on an intention-to-treat basis. Analyses revealed that craving was a significant predictor of daily drinking and baseline levels of depression were the best predictor of daily craving. There was no significant improvement in model fit when treatment group was added both in models of daily craving and daily drinking. Daily alcohol consumption was best predicted by a model incorporating baseline dependence and depression scores, and daily craving, entered as a time-varying covariate. However, there was a significant craving x time x treatment interaction (t = -3.365, df = 4413.712, P < 0.001), suggesting that at higher levels of craving drinking was reduced at a significantly greater rate with naltrexone compared to acamprosate. CONCLUSIONS: Naltrexone had a greater effect on drinking when craving was high. These results support the role of naltrexone in reducing craving when that craving is highly salient. The role of acamprosate in reducing craving was not supported by these findings. 相似文献
43.
44.
BACKGROUND & AIMS: The functional significance of intestinal hyperplasia stimulated by insulin-like growth factor (IGF)-I is unclear and has not been studied in a model of mucosal atrophy induced by total parenteral nutrition (TPN). The aim of this study was to determine how IGF-I affects intestinal structure and epithelial function in the absence of luminal nutrition caused by TPN. METHODS: Rats were maintained with TPN with or without IGF-I (800 micrograms/day), and jejunal histology and epithelial ion transport were measured after 5 days. In a third TPN group without IGF-I, a short-term dose of IGF-I was added during in vitro flux chamber experiments. RESULTS: Rats given TPN with IGF-I had greater jejunal mucosal weight, greater protein and DNA content, and increased villus height and crypt depth compared with rats given TPN only. TPN increased ionic permeability and ion transport responses to secretory and absorptive agents. IGF-I in vivo reversed most of these changes; IGF-I in vitro enhanced sodium-dependent glucose absorption but had no other effects. CONCLUSIONS: Coinfusion of recombinant human IGF-I with TPN solution stimulates intestinal hyperplasia and attenuates transport changes induced by TPN. The latter effect seems to be primarily associated with the growth state of the epithelium. (Gastroenterology 1996 Dec;111(6):1501-8) 相似文献
45.
46.
Sara Akhavanfard Sara O. Vargas Moonjoo Han Mai Nitta Clarice B. Chang Long P. Le Ladan Fazlollahi Quan Nguyen Yunqing Ma Arjola Cosper Dora Dias‐Santagata Jae Y. Han Kristin Bergethon Darrell R. Borger Leif W. Ellisen Scott L. Pomeroy Daniel A. Haber Miguel N. Rivera 《Genes, chromosomes & cancer》2014,53(1):67-77
47.
48.
Jonas MM Balistreri W Gonzalez-Peralta RP Haber B Lobritto S Mohan P Molleston JP Murray KF Narkewicz MR Rosenthal P Schwarz KB Barton BA Shepherd JA Mitchell PD Duggan C 《Hepatology (Baltimore, Md.)》2012,56(2):523-531
Weight loss and changes in growth are noted in children treated with interferon alpha (IFN-α). The aim of this study was to prospectively determine changes in weight, height, body mass index (BMI), and body composition during and after treatment of children with hepatitis C virus (HCV). Children treated with pegylated interferon alpha-2a (Peg-IFN-α2a) ± ribavirin in the Pediatric Study of Hepatitis C (PEDS-C) trial underwent anthropometric measurements, dual-energy X-ray absorptiometry scan, as well as dietary and activity assessments during and after treatment. One hundred and fourteen (55% male) children, with a mean age of 11 ± 3 years, were randomized, and 107 received treatment for at least 24 weeks. Subjects were divided into three groups according to duration of treatment: 24 (N = 14), 48 (N = 82), or 72 (N = 11) weeks. Decrements of up to 0.50 z score were observed for weight, height, and BMI while on therapy among all groups (P ≤ 0.01, compared to baseline). In the group treated for 48 weeks, 29 (33%) subjects had greater than 0.5-unit decrement in height-for-age z (HAZ) score. Though weight-for-age and BMI z scores returned to baseline after cessation of therapy, mean HAZ score was slower to rebound, still lower than baseline at 96 weeks post-therapy for the long-treatment duration group (P = 0.03) and lower than baseline in most children treated for 48 weeks. Percent body fat, fat-free mass z scores, and triceps skinfold z scores decreased with therapy. Dietary energy intake and levels of physical activity did not change during treatment. CONCLUSIONS: Peg-IFN-α2a was associated with significant changes in body weight, linear growth, BMI, and body composition in children. These effects were generally reversible with cessation of therapy, although HAZ scores had not returned to baseline after 2 years of observation in many. Longer term growth data are needed among children treated for chronic HCV. 相似文献
49.
PS Spencer K Vandemaele M Richer VS Palmer S Chungong M Anker Y Ayana ML Opoka BN Klaucke A Quarello JK Tumwine 《African health sciences》2013,13(2):183-204
Background
Nodding Syndrome is a seizure disorder of children in Mundri County, Western Equatoria, South Sudan. The disorder is reported to be spreading in South Sudan and northern Uganda.Objective
To describe environmental, nutritional, infectious, and other factors that existed before and during the de novo 1991 appearance and subsequent increase in cases through 2001.Methods
Household surveys, informant interviews, and case-control studies conducted in Lui town and Amadi village in 2001–2002 were supplemented in 2012 by informant interviews in Lui and Juba, South Sudan.Results
Nodding Syndrome was associated with Onchocerca volvulus and Mansonella perstans infections, with food use of a variety of sorghum (serena) introduced as part of an emergency relief program, and was inversely associated with a history of measles infection. There was no evidence to suggest exposure to a manmade neurotoxic pollutant or chemical agent, other than chemically dressed seed intended for planting but used for food. Food use of cyanogenic plants was documented, and exposure to fungal contaminants could not be excluded.Conclusion
Nodding Syndrome in South Sudan has an unknown etiology. Further research is recommended on the association of Nodding Syndrome with onchocerciasis/mansonelliasis and neurotoxins in plant materials used for food. 相似文献50.
Alavi M Grebely J Matthews GV Petoumenos K Yeung B Day C Lloyd AR Van Beek I Kaldor JM Hellard M Dore GJ Haber PS;ATAHC Study Group 《Journal of gastroenterology and hepatology》2012,27(5):957-965
Background and Aim: Pegylated interferon (PEG‐IFN) treatment for hepatitis C virus (HCV) infection has neuropsychiatric side effects. Data on the effect of HCV treatment on mental health among injecting drug users (IDUs) are limited. We assessed mental health during treatment of recently acquired HCV, within a predominantly IDU population. Methods: Participants with HCV received PEG‐IFN‐α‐2a (180 µg/week) for 24 weeks; HCV/HIV received PEG‐IFN with ribavirin. Depression was assessed using the Mini‐International Neuropsychiatric Interview (MINI). Logistic regression was used to identify factors associated with depression at enrolment and during treatment. Also, the effect of depression prior to and during treatment on sustained virological response (SVR) was assessed. Results: Of 163 participants, 111 received treatment (HCV, n = 74; HCV/HIV, n = 37), with 76% ever reporting IDU. At enrolment, 16% had depression (n = 25). In adjusted analysis, depression at enrolment occurred less often in participants full‐/part‐time employed (adjusted odds ratio [AOR] 0.23; 95% confidence interval [CI]: 0.06, 0.82, P = 0.023) and more often in recent IDUs (AOR 3.04; 95% CI: 1.19, 7.72, P = 0.019). During treatment, 35% (n = 31) developed new‐onset depression. In adjusted analysis, poorer social functioning (higher score) was associated with new‐onset depression (score ≤ 9 vs score ≥ 17; OR 5.69; 95% CI: 1.61, 20.14, P = 0.007). SVR was similar among participants with and without depression at enrolment (60% vs 61%, P = 0.951) and in those with and without new‐onset depression (74% vs 63%, P = 0.293). Conclusions: Although depression at enrolment and during treatment was common among participants with recent HCV, neither influenced SVR. Participants with poor social functioning may be most at risk of developing depression during HCV therapy. 相似文献